NCT05296564 2025-10-02Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersHadassah Medical OrganizationPhase 1/2 Recruiting3 enrolled
NCT04551885 2023-09-21FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated12 enrolled
NCT03970382 2022-08-18A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid TumorsPACT Pharma, Inc.Phase 1 Suspended21 enrolled